Evidence map›Paper›PMID 32178252›Full record

ArticleCancers2020

Predictive Role of MRI and

Anna Myriam Perrone, Giulia Dondi, Manuela Coe, Martina Ferioli, Silvi Telo, Andrea Galuppi, Eugenia De Crescenzo, Marco Tesei, Paolo Castellucci, Cristina Nanni and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Anna Myriam PerroneGynecologic Oncology Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Giulia DondiGynecologic Oncology Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Manuela CoeDepartment of Specialized, Diagnostic, and Experimental Medicine, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Martina FerioliRadiotherapy Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Silvi TeloNuclear Medicine Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Andrea GaluppiCentro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR) University of Bologna, 40138 Bologna, Italy.
Eugenia De CrescenzoGynecologic Oncology Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Marco TeseiGynecologic Oncology Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Paolo CastellucciNuclear Medicine Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Cristina NanniNuclear Medicine Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Stefano FantiCentro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR) University of Bologna, 40138 Bologna, Italy.
Alessio G MorgantiCentro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR) University of Bologna, 40138 Bologna, Italy.
Pierandrea De IacoGynecologic Oncology Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor response in locally advanced cervical cancer (LACC) is generally evaluated with MRI and PET, but this strategy is not supported by the literature. Therefore, we compared the diagnostic performance of these two techniques in the response evaluation to concurrent chemoradiotherapy (CCRT) in LACC. Patients with cervical cancer (CC) stage T2b treated with CCRT and submitted to MRI and PET/CT before and after treatment were enrolled in the study. All clinical, pathological, therapeutic, radiologic and follow-up data were collected and examined. The radiological response was analyzed and compared to the follow-up data. Data of 40 patients with LACC were analyzed. Agreement between MRI and PET/CT in the evaluation response to therapy was observed in 31/40 (77.5%) of cases. The agreement between MRI, PET/CT and follow-up data showed a Cohen kappa coefficient of 0.59 (95% CI = 0.267-0.913) and of 0.84 (95% CI = 0.636-1.00), respectively. Considering the evaluation of primary tumor response, PET/CT was correct in 97.5% of cases, and MRI in 92.5% of cases; no false negative cases were observed. These results suggest the use of PET/CT as a unique diagnostic imaging tool after CCRT, to correctly assess residual and progression disease.

Indexed as

concurrent chemoradiotherapyfollow uplocally advanced cervical cancerMRIPET/CTtreatment response

Identifiers

PMID32178252
PMCPMC7139894
OpenAlexW3011997830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.